30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

1Q13 Revenue: aap Implantate

€10.4MM (~US $13.4MM), +5% (Trauma ~$1.94MM, +15%: LOQTEQ ~$0.5MM, +300%)

  • Entered a multi-year supply and development agreement for certain biomaterial products
  • Entered into a joint venture to co-develop resorbable magnesium trauma products with Eontec
  • Entered into a global license agreement with BiosCompass for rights to Adcon
  • Appointed distributor for LOQTEQ in China
  • Commenced U.S. beta launch of LOQTEQ (full launch could occur in 4Q)
  • Received FDA 510(k) clearance for BonOs R and BonOsR Genta bone cements